Rabih Halabi, MD
Pulmonary Disease · Falls Church, VANPI 1598972861
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $499,648 of the $604,069 with a category attached, or 82.7%. 34 manufacturers reported payments, led by Sanofi at 56.3% of the total. Among pulmonary disease clinicians in VA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 784 payments — averaging $770.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$340K
- Regeneron Healthcare Solutions, Inc.$242K
- Genentech USA, Inc.$7K
- Regeneron$4K
- EMD Serono, Inc.$4K
- AstraZeneca$3K
- plus $5K from 28 others
What the payments were for
- Consulting fees$29,6775%
- Speaking & faculty fees$499,64883%
- Travel & lodging$55,2939%
- Food & beverage$18,9673%
- Education$4830%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 278 | $340,168 |
| Regeneron Healthcare Solutions, Inc. | 300 | $242,299 |
| Genentech USA, Inc. | 26 | $6,690 |
| Regeneron | 2 | $3,672 |
| EMD Serono, Inc. | 1 | $3,570 |
| AstraZeneca | 36 | $2,755 |
| Insmed, Inc. | 8 | $1,520 |
| GSK | 54 | $1,214 |
| Sanofi-aventis U.S. LLC | 4 | $284 |
| Baxter Healthcare | 9 | $238 |
| Boehringer Ingelheim | 12 | $236 |
| Pulmonx Corporation | 2 | $187 |
| Verona Pharma, Inc. | 3 | $178 |
| Amgen | 7 | $166 |
| Mylan Specialty L.p. | 7 | $144 |
| Johnson & Johnson | 5 | $94 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $79 |
| Novartis | 4 | $76 |
| Viatris Specialty LLC | 1 | $59 |
| Grifols USA, LLC | 2 | $51 |
| United Therapeutics Corporation | 2 | $49 |
| Bayer | 2 | $43 |
| Teva Pharmaceuticals USA, Inc. | 1 | $34 |
| Philips North America LLC | 2 | $32 |
| Mallinckrodt Hospital Products Inc. | 1 | $29 |
| Merck | 2 | $29 |
| Shionogi Inc | 1 | $27 |
| Pfizer | 2 | $27 |
| Actelion Pharmaceuticals US, Inc. | 2 | $24 |
| Sunovion Pharmaceuticals Inc. | 1 | $24 |
| E.r. Squibb & Sons, L.L.C. | 1 | $20 |
| Medical Graphics Corporation | 1 | $19 |
| Electromed, Inc. | 1 | $16 |
| Gilead | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DUPIXENT$634,142
- Tepmetko$3,570
- XOLAIR$1,350
- NUCALA$408
- FASENRA$328
- CHARTIS CATHETER$161
- PULMONX CHARTIS TABLET CONSOLE$161
- ZEPHYR ENDOBRONCHIAL VALVE$161
- ZEPHYR DELIVERY CATHETER$161
- Ohtuvayre$130
How this compares
$604,069 in reported general payments places this provider in the 95th percentile of 317 pulmonary disease providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 134 | $530,457 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 227 | $246,464 |
| OfevNintedanib Esylate | 12 | $145,305 |
| Pirfenidone | 22 | $100,348 |
| Fasenra PenBenralizumab | 15 | $85,469 |
| Dupixent SyringeDupilumab | 14 | $73,334 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 43 | $38,007 |
| Spiriva RespimatTiotropium Bromide | 41 | $37,281 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 41 | $34,649 |
| SymbicortBudesonide/Formoterol Fumarate | 62 | $21,744 |
| Arnuity ElliptaFluticasone Furoate | 45 | $19,051 |
| Qvar RedihalerBeclomethasone Dipropionate | 39 | $15,544 |
| EliquisApixaban | 12 | $13,588 |
| Breo ElliptaFluticasone/Vilanterol | 15 | $13,147 |
| Incruse ElliptaUmeclidinium Bromide | 20 | $12,403 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Arnuity Ellipta, Breo Ellipta, Incruse Ellipta, Anoro Ellipta | $1,214 | $301,405318 claims |
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat | $236 | $217,23594 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $2,755 | $59,751105 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $34 | $15,54439 claims |
| PfizerEliquis | $27 | $13,58812 claims |
| Johnson & JohnsonXarelto | $94 | $11,00115 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 317 pulmonary disease providers in Virginia.
Other pulmonary disease in Falls Church
- Steven NathanFalls Church$1.5M
- Vikramjit KhangooraFalls Church$49K
- Shambhu AryalFalls Church$48K
- Anne BrownFalls Church$31K
- Omar MinaiHopewell$1.3M
- Eric LibreAnnandale$302K
- Sujoy GillRichmond$296K
- Imre NothCharlottesville$256K
- Carlos SilvaChesapeake$245K
- Vijay SubramaniamWilliamsburg$228K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.